Vasa Therapeutics
Transformative therapies for vascular disease.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | $6.0m | Seed | |
| Total Funding | 000k | ||
Related Content
Vasa Therapeutics is a preclinical-stage biopharmaceutical company focused on developing therapeutics for diseases related to cardiovascular and metabolic aging. The company's primary drug candidate, VS-041, is an oral compound aimed at treating heart failure with preserved ejection fraction (HFpEF), a condition with significant unmet medical need. Vasa Therapeutics is pursuing a personalized medicine approach, utilizing a novel biomarker strategy to identify patients who are most likely to respond to their treatment.
The company's business model revolves around the discovery, development, and eventual commercialization of its therapeutic candidates. They are currently in the clinical trial phase, having received authorization from the UK's MHRA to initiate a first-in-human study for VS-041. Vasa Therapeutics has successfully raised seed funding to advance its research and development activities. The company collaborates with research institutions and seeks regulatory approvals to bring its products to market, targeting the large and growing population affected by cardiovascular diseases.
Keywords: biopharmaceutical, cardiovascular diseases, metabolic aging, heart failure, HFpEF, clinical trials, personalized medicine, drug development, therapeutics, biomarker